Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

December 22, 2017 07:00 ET | Source: RedHill Biopharma Ltd.

RedHill Biopharma Announces Initiation of Phase IIa Study with ABC294640 (YELIVA®) for Cholangiocarcinoma at Mayo Clinic and MD Anderson

YELIVA®, a proprietary, first-in-class SK2 inhibitor, was granted FDA Orphan Drug designation for the treatment of cholangiocarcinomaCholangiocarcinoma (bile duct cancer) is a highly lethal malignancy...
December 05, 2017 09:30 ET | Source: RedHill Biopharma Ltd.

RedHill Biopharma Provides 2017 Year-End Business Update

TEL-AVIV, Israel and RALEIGH, N.C., Dec. 05, 2017 (GLOBE NEWSWIRE) -- RedHill Biopharma Ltd. (NASDAQ:RDHL) (Tel-Aviv Stock Exchange:RDHL) (“RedHill” or the “Company”), a specialty biopharmaceutical...
November 13, 2017 13:16 ET | Source: RedHill Biopharma Ltd.

RedHill Biopharma Announces Closing of Public Offering of its American Depositary Shares

TEL-AVIV, Israel and RALEIGH, N.C., Nov. 13, 2017 (GLOBE NEWSWIRE) -- RedHill Biopharma Ltd. (NASDAQ:RDHL) (Tel-Aviv Stock Exchange:RDHL) (“RedHill” or the “Company”), a specialty biopharmaceutical...
November 13, 2017 07:30 ET | Source: RedHill Biopharma Ltd.

RedHill Biopharma Reports 2017 Third Quarter Financial Results

RedHill maintains a debt-free balance sheet with $39.6 million in cash1 at the end of the third quarter of 2017In addition, an underwritten public offering of the Company’s American Depositary Shares...
November 09, 2017 07:00 ET | Source: RedHill Biopharma Ltd.

RedHill Biopharma Announces Last Patient Enrolled in the Phase III Study with RHB-104 for Crohn’s Disease

Top-line results are expected to be announced in mid-2018 The Phase III study evaluating RHB-104 for Crohn’s disease (MAP US study) is a randomized, double-blind, placebo-controlled study that is...
November 08, 2017 09:13 ET | Source: RedHill Biopharma Ltd.

RedHill Biopharma Prices Public Offering of its American Depositary Shares

TEL-AVIV, Israel and RALEIGH, N.C., Nov. 08, 2017 (GLOBE NEWSWIRE) -- RedHill Biopharma Ltd. (NASDAQ:RDHL) (Tel-Aviv Stock Exchange:RDHL) (“RedHill” or the “Company”), a specialty biopharmaceutical...
November 07, 2017 16:08 ET | Source: RedHill Biopharma Ltd.

RedHill Biopharma Announces Proposed Public Offering of its American Depositary Shares

TEL-AVIV, Israel and RALEIGH, N.C., Nov. 07, 2017 (GLOBE NEWSWIRE) -- RedHill Biopharma Ltd. (NASDAQ:RDHL) (Tel-Aviv Stock Exchange:RDHL) (“RedHill” or the “Company”), a specialty biopharmaceutical...
November 06, 2017 08:00 ET | Source: RedHill Biopharma Ltd.

RedHill Biopharma to Host Third Quarter 2017 Financial Results Conference Call on November 13, 2017

TEL-AVIV, Israel and RALEIGH, N.C., Nov. 06, 2017 (GLOBE NEWSWIRE) -- RedHill Biopharma Ltd. (NASDAQ:RDHL) (Tel-Aviv Stock Exchange:RDHL) (“RedHill” or the “Company”), a specialty biopharmaceutical...
November 06, 2017 07:00 ET | Source: RedHill Biopharma Ltd.

RedHill Biopharma Announces EnteraGam® Poster Presentation at the ISPOR 20th Annual European Congress

TEL-AVIV, Israel and RALEIGH, N.C., Nov. 06, 2017 (GLOBE NEWSWIRE) -- RedHill Biopharma Ltd. (NASDAQ:RDHL) (Tel-Aviv Stock Exchange:RDHL) (“RedHill” or the “Company”), a specialty biopharmaceutical...
November 01, 2017 07:00 ET | Source: RedHill Biopharma Ltd.

RedHill Biopharma and IntelGenx Submit New Drug Application to FDA for RIZAPORT® for Migraines

RIZAPORT® is a proprietary oral thin-film formulation of rizatriptan for the treatment of acute migrainesA Prescription Drug User Fee Act (PDUFA) date is expected to be set by the FDA for the first...